These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 32125294)
1. Exquisite response to imatinib mesylate in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome: a 12-year experience of the Polish Hypereosinophilic Syndrome Study Group. Helbig G; Lewandowski K; Świderska A; Rodzaj M; Seferyńska I; Gajkowska-Kulik J Pol Arch Intern Med; 2020 Mar; 130(3):255-257. PubMed ID: 32125294 [No Abstract] [Full Text] [Related]
2. Imatinib discontinuation for hypereosinophilic syndrome harboring the FIP1L1-PDGFRA transcript. Helbig G; Soja A; Świderska A; Hus M; Kyrcz-Krzemień S Leuk Lymphoma; 2016; 57(3):708-10. PubMed ID: 26430910 [No Abstract] [Full Text] [Related]
3. Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome. Helbig G; Kyrcz-Krzemień S Am J Hematol; 2014 Jan; 89(1):115. PubMed ID: 24009127 [No Abstract] [Full Text] [Related]
4. A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome. Salemi S; Yousefi S; Simon D; Schmid I; Moretti L; Scapozza L; Simon HU Allergy; 2009 Jun; 64(6):913-8. PubMed ID: 19210352 [TBL] [Abstract][Full Text] [Related]
5. Maintenance therapy with imatinib appears necessary despite molecular remission in FIP1L1-PDGFRA fusion gene positive hypereosinophilic disorder. Ng HJ; Tan DC; Yiu RC; How GF Leuk Res; 2008 Jan; 32(1):169-71. PubMed ID: 17544504 [TBL] [Abstract][Full Text] [Related]
6. Imatinib Treatment of Lymphomatoid Papulosis Associated with Myeloproliferative Hypereosinophilic Syndrome Presenting the FIP1L1-PDGFRA Fusion Gene. García-Martínez P; Sitjas D; Llistosella E; Espinet B; Rodríguez-Rivera M; Hernandez-Muñoz M; Gallardo F; Pujol RM Acta Derm Venereol; 2017 Jul; 97(7):855-857. PubMed ID: 28374041 [No Abstract] [Full Text] [Related]
7. [Efficacy of imatinib in FIP1L1-PDGFRA positive hypereosinophilic syndrome]. Menif S; Ben Romdhane N; Hafsia R Rev Med Interne; 2008 Jan; 29(1):65-7. PubMed ID: 18036706 [TBL] [Abstract][Full Text] [Related]
8. Imatinib for the treatment of hypereosinophilic syndromes. Helbig G Expert Rev Clin Immunol; 2018 Feb; 14(2):163-170. PubMed ID: 29303368 [TBL] [Abstract][Full Text] [Related]
9. Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome. Khoury P; Desmond R; Pabon A; Holland-Thomas N; Ware JM; Arthur DC; Kurlander R; Fay MP; Maric I; Klion AD Allergy; 2016 Jun; 71(6):803-10. PubMed ID: 26797802 [TBL] [Abstract][Full Text] [Related]
10. Successful Heart Transplantation for Unreversible Endomyocardial Fibrosis Related to FIP1L1-PDGFRA Chronic Eosinophilic Leukemia. Fassnacht F; Roumier M; Fouret P; Levy V; Varnous S; Russel S; Lefevre G; Kahn JE Transplantation; 2015 Nov; 99(11):e176-7. PubMed ID: 26492057 [No Abstract] [Full Text] [Related]
11. [FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutant of PDGFRA gene: a case report and literature review]. Qu SQ; Wang Y; Sun XJ Zhonghua Xue Ye Xue Za Zhi; 2013 Feb; 34(2):159-61. PubMed ID: 23611226 [No Abstract] [Full Text] [Related]
12. Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1-PDGFRA fusion transcript--results of Polish multicentre study. Helbig G; Moskwa A; Hus M; Piszcz J; Swiderska A; Urbanowicz A; Całbecka M; Gajkowska J; Seferyńska I; Hałasz M; Woszczyk D; Markiewicz M; Krzemień S Hematol Oncol; 2010 Jun; 28(2):93-7. PubMed ID: 19728396 [TBL] [Abstract][Full Text] [Related]
13. Rapid reversion of eosinophilic gastroenteritis associated with FIP1L1-PDGFRA fusion after targeted therapy with imatinib. Pitini V; Sturniolo G; Cavallari V; Arrigo C Br J Haematol; 2006 Jan; 132(2):123. PubMed ID: 16398645 [No Abstract] [Full Text] [Related]
17. [Hypereosinophilic syndrome and Löffler endocarditis caused by FIP1L-PDGFRA rearrangement: effectiveness of imatinib mesylate therapy]. Mauri M; García M; Reynaga E; Ramila E Med Clin (Barc); 2007 Jun; 129(4):159. PubMed ID: 17663975 [No Abstract] [Full Text] [Related]
18. [The activation of JAK/STAT signal pathway in hypereosinophilic syndrome and the patients therapeutic response to imatinib]. Li B; Zhang GS; Dai CW; Pei MF Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):448-52. PubMed ID: 15854548 [TBL] [Abstract][Full Text] [Related]
19. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients. Helbig G; Stella-Hołowiecka B; Majewski M; Całbecka M; Gajkowska J; Klimkiewicz R; Moskwa A; Grzegorczyk J; Lewandowska M; Hołowiecki J Br J Haematol; 2008 Apr; 141(2):200-4. PubMed ID: 18307562 [TBL] [Abstract][Full Text] [Related]
20. FIP1L1-PDGFRA positive chronic eosinophilic leukaemia and associated central nervous system involvement. Williams C; Kalra S; Nath U; Bown N; Wilson V; Wilkins BS; Neylon AJ J Clin Pathol; 2008 May; 61(5):677-80. PubMed ID: 18256119 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]